tirzepatide discontinuation vs Semaglutide: The tolerability trade-off. SURMOUNT-5 data shows tirzepatide had 50% lower GI-related (2.7% vs 5.6%) but higher injection site reactions (8.6% vs 0.3%). A key choice for your journey What are the recommended guidelines

DPP-4 inhibitors, such as sitagliptin, are associated with intermediate efficacy in terms of glycemic control, are weight neutral and have a low risk of hypoglycemia [6]

Pancreatitis Seek urgent medical help if you have abdominal pain

Tambin puede consultar la acreditacin de Farmacia Digital de la NABP (National Association of Boards of Pharmacy) y los sitios web verificados con dominio .pharmacy

The dual-action mechanism of tirzepatide targets both GLP-1 and GIP pathways simultaneously, creating a more comprehensive metabolic effect than single-pathway medications

Injections are administered under the skin of the abdomen, thigh, or upper arm, in a different location each time